PDUFA Pilots: Risk/Benefit Plan Takes Off As “Continuous” Applications Stop
Executive Summary
FDA's proposals for renewal of the Prescription Drug User Fee Act will continue the program's function as an incubator of new regulatory approaches by the agency
You may also be interested in...
Fast Track Speeds Approval, Tufts Finds; Therapeutic Category Also Key
FDA’s fast track program may be the most successful of FDA’s user fee-era regulatory initiatives aimed at speeding new drug reviews, an analysis by the Tufts Center for the Study of Drug Development suggests.
Fast Track Speeds Approval, Tufts Finds; Therapeutic Category Also Key
FDA’s fast track program may be the most successful of FDA’s user fee-era regulatory initiatives aimed at speeding new drug reviews, an analysis by the Tufts Center for the Study of Drug Development suggests.
FDA’s Trade Name Pilot Should Include Third-Party Reviews, Industry Says
Foreseeing battles over FDA and industry trade name discrepancies in a proposed pilot program, industry representatives are recommending that an independent, third-party review take place